Newcastle University

Publications

Year: 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1989 1988 1987 1986 1984 1983 1980 1979

• Coulthard, S., Rabello, C., Robson, J., Howell, C., Minto, L., Middleton, P., Gandhi, M., Jackson, G., McLelland, J., O'Brien, H., Smith, S., Reid, M., Pearson, A., Hall, A. A comparison of molecular and enzyme-based assays for the detection of thiopurine methyltransferase mutations. British Journal of Haematology 2000, 110(3), 599-604.
• Proctor SJ, Taylor PRA. A practical guide to continuous population-based data collection (PACE): a process facilitating uniformity of care and research into practice. QJM: An International Journal of Medicine 2000, 93(2), 67-73.
• Sim E, Payton M, Noble M, Minchin R. An update on genetic, structural and functional studies of arylamine N-acetyltransferases in eucaryotes and procaryotes. Human Molecular Genetics 2000, 9(16), 2435-2441.
• Ozanne, D. M., Brady, M. E., Cook, S., Gaughan, L., Neal, D. E., Robson, C. N. Androgen receptor nuclear translocation is facilitated by the f-actin cross-linking protein filamin. Molecular Endocrinology 2000, 14(10), 1618-1626.
• Luger SM, O'Brien SG, Ratajzcak J, Ratajczak MZ, Mick R, Nowell PC, Magee D, Stadtmauer EA, Goldman JM, Gewirtz AM. Bone marrow purging with C-MYB targeted oligodeoxynucleotides: Results, and long term follow-up, of a pilot study in chronic myelogenous leukemia patients. In: BLOOD. 2000.
• Lu, X., Errington, J., Chen, V., Curtin, N. J., Boddy, A. V., Newell, D. R. Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell lines. Clinical Cancer Research 2000, 6(1), 271-277.
• Monks, N., Calvete, J., Curtin, N.J., Blakey, D., East, S., Newell, D.R. Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT). British Journal of Cancer 2000, 83(2), 267-269.
• White KD, Ince PG, Lusher M, Lindsey JC, Cookson M, Bashir R, Shaw PJ, Bushby KMD. Clinical and pathologic findings in hereditary spastic paraparesis with spastin mutation. Neurology 2000, 55(1), 89-94.
• Hughes, A. N., Griffin, M. J., Newell, D. R., Calvert, A. H., Johnston, A., Kerr, B., Lee, C., Liang, B., Boddy, A. V. Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq(TM)) and paclitaxel. British Journal of Cancer 2000, 82(9), 1519-1527.
• Woodward ER, Buchberger A, Clifford SC, Hurst LD, Affara NA, Maher ER. Comparative sequence analysis of the VHL tumor suppressor gene. Genomics 2000, 65(3), 253-265.
• Stavrianos SD, McLean NR, Kelly CG, Fellows S. Cutaneous metastasis to the head and neck from colonic carcinoma. European Journal of Surgical Oncology 2000, 26(5), 518-519.
• Legraverend M, Tunnah P, Noble M, Ducrot P, Ludwig O, Grierson DS, Leost M, Meijer L, Endicott J. Cyclin-dependent kinase inhibition by new C-2 alkynylated purine derivatives and molecular structure of a CDK2-inhibitor complex. Journal of Medicinal Chemistry 2000, 43(7), 1282-1292.
• Jackson A, Carrara P, Duke V, Sinclair PB, Papaioannou M, Harrison CJ, Foroni L. Deletion of 6q16-q21 in human lymphoid maligancies: a mapping and deletion analysis. Cancer Research 2000, 60(11), 2775-2779.
• Griffin RJ, Arris CE, Calvert AH, Curtin NJ, Jewsbury P, Endicott JA, Gibson AE, Boyle FT, Golding BT, Grant S, Johnson LN, Noble MEM, Newell DR, Lawrie A. Design, synthesis, and biological evaluation of O-6-alkylguanine and O-4-alkylpyrimidine cyclin-dependent kinase inhibitors. Abstracts of Papers of the American Chemical Society 2000, 219(2), U55 296-MEDI.
• Adams I, Taylor PRA, Jackson GH, Angus B, Watson P, Mounter P, McKay P, Dickinson AM, Oliver K, Jack F. Development of a novel prognostic score for mantle cell lymphoma. In: BLOOD. 2000.
• Smith, P., Marshman, E., Newell, D.R., Curtin, N.J. Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport. British Journal of Cancer 2000, 82(4), 924-930.
• Lovat, P.E., Ranalli, M., Bernassola, F., Tilby, M., Malcolm, A.J., Pearson, A.D.J., Piacentini, M., Melino, G., Redfern, C.P.F. Distinct properties of fenretinide and CD437 lead to synergistic responses with chemotherapeutic reagents. Medical and Pediatric Oncology 2000, 35(6), 663-668.
• Lovat, P.E., Ranalli, M., Annichiarrico-Petruzzelli, M., Bernassola, F., Piacentini, M., Malcolm, A.J., Pearson, A.D.J., Melino, G., Redfern, C.P.F. Effector mechanisms of fenretinide-induced apoptosis in neuroblastoma. Experimental Cell Research 2000, 260(1), 50-60.
• Woodward ER, Clifford SC, Astuti D, Affara NA, Maher ER. Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes. Journal of Medical Genetics 2000, 37(5), 348-53.
• Redfern, C.P.F., Slough, A., Dean, B., Brice, J., Jones, P. Fat and body condition migrating Redwings Turdus iliacus. Journal of Avian Biology 2000, 31(2), 197-205.
• Edmondson RJ, Monaghan JM, Davies BR. Gonadotrophins directly stimulate the proliferation of human ovarian surface epithelial cells. In: BRITISH JOURNAL OF CANCER. 2000.
• Stavrianos SD, Ragbir M, McLean NR, Kelly CG, Soames JV. Head and neck skin involvement by non-cutaneous head and neck cancers: Free flap reconstruction. European Journal of Surgical Oncology 2000, 26(6), 594-598.
• Heer R, Dobson D, Plusa SM. How to alter surgical practice? The use of guidelines to encourage day-case haemorrhoidectomy. Journal of The Royal College of Surgeons of Edinburgh 2000, 45(6), 369-370.
• Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, Maxwell PH. Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. Journal of Biological Chemistry 2000, 275(33), 25733-25741.
• Arris CE, Boyle FT, Calvert AH, Curtin NJ, Endicott JA, Garman EF, Gibson AE, Golding BT, Grant S, Griffin RJ, Jewsbury P, Johnson LN, Lawrie AM, Newell DR, Noble MEM, Sausville EA, Schultz R, Yu W. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. Journal of Medicinal Chemistry 2000, 43(15), 2797-2804.
• Arris, C. E., Boyle, F., Calvert, A. H., Curtin, N. J., Endicott, J. A., Garman, E. F., Gibson, A. E., Golding, B. T., Grant, S., Griffin, R. J., Jewsbury, P., Johnson, L., Lawrie, A., Newell, D. R., Noble, M., Sausville, E., Schultz, R., Yu, W. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. Journal of Medicinal Chemistry 2000, 43(15), 2797-2804.
• Johnstone EC, Griffin MJ, Lind MJ, Boddy AV. Ifosfamide metabolism and DNA damage in tumour and peripheral blood lymphocytes of breast cancer patients. Cancer Chemotherapy and Pharmacology 2000, 46(6), 433-441.
• Steele IA, Edmondson RJ, Bolger B, Bulmer J, Leung HY, Davies BR. Induction of expression of FGF receptor 2-IIIb in ovarian cancer. In: BRITISH JOURNAL OF CANCER. 2000.
• Wedge SR, Ogilvie DJ. Inhibition of VEGF signal transduction. Identification of ZD4190. Advances in Experimental Medicine and Biology 2000, 476, 305-310.
• Molloy CA, May FEB, Westley BR. Insulin receptor substrate-1 expression is regulated by estrogen in the MCF-7 human breast cancer cell line. Journal of Biological Chemistry 2000, 275(17), 12565-12571.
• Sinclair PB, Nacheva EP, Leversha M, Telford N, Chang J, Reid A, Bench A, Champion K, Huntley B, Green AR. Large deletions at the t(9;22) breakpoint are common and may define a poor-prognosis subgroup of patients with chronicmyeloid leukemia. Blood 2000, 95(3), 738-744.
• Francis RM, Baillie SP, Chuck AJ, Crook PR, Daymond T, Dunn N, Fordham JN, Kelly C, Rodgers A. Management of osteoporosis in patients with hip fractures. QJM-An International Journal of Medicine 2000, 93(8), 501-506.
• Boddy, A. V., Yule, S. M. Metabolism and pharmacokinetics of oxazaphosphorines. Clinical Pharmacokinetics 2000, 38(4), 291-304.
• Clark R, Byatt S-A, Bennett CF, Brama M, Martineau M, Moorman AV, Roberts K, Secker-Walker LM, Richards S, Eden OB, Goldstone AH, Harrison CJ. Monosomy 20 as a pointer to dicentric (9;20) in acute lymphoblastic leukaemia. Leukemia 2000, 14(2), 241-246.
• Lindsey JC, Lusher ME, McDermott CJ, White KD, Reid E, Rubinsztein DC, Bashir R, Hazan J, Shaw PJ, Bushby KMD. Mutation analysis of the spastin gene (SPG4) in patients with hereditary spastic paraparesis. Journal of Medical Genetics 2000, 37(10), 759-765.
• Paleri V, Lindsey L. Oral ulcers caused by hydroxyurea. Journal of Laryngology and Otology 2000, 114(12), 976-977.
• Dresner SM, Griffin SM. Pattern of recurrence following radical oesophagectomy with two-field lymphadenectomy. British Journal of Surgery 2000, 87(10), 1426-1433.
• Thomas HD, Lind M, Ford J, Bleehen N, Calvert AH, Boddy AV. Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist Cereport (RMP-7) for the treatment of brain tumours. Cancer Chemotherapy and Pharmacology 2000, 45(4), 284-290.
• Middleton PG, Norden J, Levett DL, Levasseur M, Miller S, Irving JAE, Wood A, Reid MM, Taylor PRA, Proctor SJ. Population-based study of the pattern of molecular markers of minimal residual disease in childhood and adult acute lymphoblastic leukemia: An assessment of the practical difficulty of representative sampling for trial purposes. Medical and Pediatric Oncology 2000, 34(2), 106-110.
• Delaney, C.A., Wang, L., Kyle, S., White, A.W., Calvert, A.H., Curtin, N.J., Durkacz, B.W., Hostomsky, Z, Newell, D.R. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clinical Cancer Research 2000, 6(7), 2860-2867.
• Thomas HD, Boddy AV, English M, Hobson R, Imeson J, Lewis I, Morland B, Pearson ADJ, Pinkerton R, Price L, Stevens M, Newell DR. Prospective validation of renal function-based carboplatin dosing in children with cancer: A United Kingdom Children's Cancer Study Group Trial. Journal of Clinical Oncology 2000, 18(21), 3614-3621.
• Lewis, I. J., Weeden, S., Machin, D., Stark, D., Craft, A. W. Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. Journal of Clinical Oncology 2000, 18(24), 4028-4037.
• Campbell-Hewson, Q., Lovat, P.E., Malcolm, A.J., Pearson, A.D.J., Redfern, C.P.F. Receptor mechanisms mediating differentiation and proliferation effects of retinoids on neuroblastoma cells. Neuroscience Letters 2000, 279(2), 113-116.
• Griffin, R. J., Arris, C. E., Bleasdale, C. , Boyle, F., Calvert, A. H., Curtin, N. J., Dalby, C., Kanugula, S., Lembicz, N., Newell, D. R., Pegg, A., Golding, B. T. Resistance-modifying agents. 8. Inhibition of O⁶-alkylguanine-DNA alkyltransferase by O⁶-alkenyl-, O⁶-cycloalkenyl-, and O⁶-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O⁶-(1-cyclopentenylmethyl) guanine. Journal of Medicinal Chemistry 2000, 43(22), 4071-4083.
• White, A.W., Almassy, R., Calvert, A.H., Curtin, N.J., Griffin, R.J., Hostomsky, Z., Maegley, K., Newell, D.R., Srinivasan, S, Golding, B.T. Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase. Journal of Medicinal Chemistry 2000, 43(22), 4084-4097.
• Barlow, H. C., Bowman, K. J., Curtin, N. J., Calvert, A. H., Golding, B. T., Huang, B., Loughlin, P. J., Newell, D. R., Smith, P. G., Griffin, R. J. Resistance-modifying agents. Part 7: 2,6-Disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines that inhibit nucleoside transport in the presence of α1-acid glycoprotein (AGP). Bioorganic and Medicinal Chemistry Letters 2000, 10(6), 585-589.
• Skinner R, Cotterill SJ, Stevens MCG. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. British Journal of Cancer 2000, 82(10), 1636-1645.
• Zeidler C, Welte K, Barak Y, Barriga F, Bolyard AA, Boxer L, Cornu G, Cowan MJ, Dale DC, Flood T, Freedman M, Gadner H, Mandel H, O'Reilly RJ, Ramenghi U, Reiter A, Skinner R, Vermylen C, Levine JE. Stem cell transplantation in patients with severe congenital neutropenia without evidence of leukemic transformation. Blood 2000, 95(4), 1195-1198.
• Sinclair JC, Sandy J, Delgoda R, Sim E, Noble MEM. Structure of arylamine N-acetyltransferase reveals a catalytic triad. Nature Structural Biology 2000, 7(7), 560-564.
• Bentley J, Arris CE, Boyle FT, Calvert AH, Curtin NJ, Endicott JA, Gibson AE, Golding BT, Grant S, Griffin RJ, Jewsbury PJ, Johnson LN, Noble MEM, Newell DR. Structure-activity relationships and cellular effects of novel purine- and pyrimidine-based cyclin dependent kinase inhibitors. Clinical Cancer Research 2000, 6, 328.
• Lovat, P.E., Ranalli, M., Bernassola, F., Tilby, M.J., Malcolm, A.J., Pearson, A.D.J., Piacentini, M, Melino, G., Redfern, C.P.F. Synergistic induction of apoptosis of neuroblastoma by fenretinide or CD437 in combination with chemotherapeutic drugs. International Journal of Cancer 2000, 88(6), 977-985.
• Wang XN, Taylor PRA, Skinner R, Jackson GH, Proctor SJ, Hedley D, Dickinson AM. T-cell frequency analysis does not predict the incidence of graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Transplantation 2000, 70(3), 488-493.
• Holler E, Schulz U, Jarvis M, Dickinson AM, Sviland L, Hromadnikova I, Jackson G, Konur A, Eissner G, Andreesen R. The detection of keratinocyte apoptosis in a human skin explant assays for prediction of graft-versus-host disease. In: BLOOD. 2000.
• Newton JL, Allen A, Westley BR, May FEB. The human trefoil peptide, TFF1, is present in different molecular forms that are intimately associated with mucus in normal stomach. Gut 2000, 46(3), 312-320.
• May FEB, Semple J, Newton JL, Westley BR. The human two domain trefoil protein, TFF2, is glycosylated in vivo in the stomach. Gut 2000, 46(4), 454-459.
• Watson JP, Bennett MK, Griffin SM, Matthewson K. The tissue effect of argon plasma coagulation on esophageal and gastric mucosa. In: United European Gastroenterology Week. 2000, Birmingham, United Kingdom: Moseby.
• Greaves MF, Eden OB, Harrison CJ, Moorman AV, Roman E, Simpson J, Craft A, Hale J, Kernahan J, Reid M, Windebank K, Pearson A, Skinner R, As part of the United Kingdom Childhood Cancer Study Group. The United Kingdom Childhood Cancer Study: objectives, materials and methods. British Journal of Cancer 2000, 82(5), 1073-1102.
• Mann, J. R., Raafat, F., Robinson, K., Imeson, J., Gornall, P., Sokal, M., Gray, E., McKeever, P., Hale, J., Bailey, S., Oakhill, A. The United Kingdom Children's Cancer Study Group's second germ cell tumor study: Carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. Journal of Clinical Oncology 2000, 18(22), 3809-3818.
• Williams NW, Kelly C, McLean NR. Trans-osseous passage of head and neck brachytherapy tubes. British Journal of Plastic Surgery 2000, 53(6), 520-521.
• Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Curwen JO, Hennequin LF, Thomas AP, Stokes ESE, Curry B, Richmond GHP, Wadsworth PF. ZD4190: An orally active inhibitor of vascular endothelial growth factor signalling with broad-spectrum antitumor efficacy. Cancer Research 2000, 60(4), 970-975.